Trending...
- Food Journal Magazine Releases Its 'Best Food In Los Angeles Dining' Editorial Section
- Rande Vick Introduces Radical Value, Challenging How Brands Measure Long-Term Value
- Talented Learning Unveils 2026 "Office Hours for LMS Buyers" Webinar Series
~ Congruence Therapeutics, a biotechnology company focused on developing small molecule correctors to rescue aberrant protein function, has announced their participation in the International Congress of Parkinson's Disease and Movement Disorders 2024 Meeting. The event will take place from September 27th to October 1st, 2024 in Philadelphia, PA.
The company's Chief Scientific Officer, Sharath Hegde, Ph.D., shared that mutations of the GBA1 gene are considered the most significant genetic risk factor for Parkinson's Disease. Congruence is dedicated to addressing this issue by utilizing their proprietary platform Revenir™ to discover potent and brain-penetrant allosteric GCase correctors. These molecules have shown promising results in preclinical studies.
More on The PennZone
At the conference, Congruence will present a poster titled "Identification of Allosteric GCase Correctors using Revenir™ for the treatment of GBA1-Parkinson's Disease." The abstract number for this presentation is 791 and it is scheduled for Sunday, September 29th from 1-3PM. Jeremy Dupaul-Chicoine, Associate Director of Biology at Congruence Therapeutics, will be the presenting author.
The company's efforts to develop effective treatments for GBA1-Parkinson's Disease have yielded positive results and they continue to optimize their chemical leads in hopes of discovering potential clinical candidates. This presentation at the International Congress of Parkinson's Disease and Movement Disorders serves as a testament to Congruence Therapeutics' dedication to improving the lives of those affected by this debilitating disease.
The company's Chief Scientific Officer, Sharath Hegde, Ph.D., shared that mutations of the GBA1 gene are considered the most significant genetic risk factor for Parkinson's Disease. Congruence is dedicated to addressing this issue by utilizing their proprietary platform Revenir™ to discover potent and brain-penetrant allosteric GCase correctors. These molecules have shown promising results in preclinical studies.
More on The PennZone
- Secondesk Launches Powerful AI Tutor That Speaks 20+ Languages
- Automation, innovation in healthcare processes featured at international conference in Atlanta
- A High-Velocity Growth Story Emerges in Marine and Luxury Markets
- $26 Billion Global Market by 2035 for Digital Assets Opens Major Potential for Currency Tech Company with ATM Expansion and Deployment Plans Underway
- Peernovation 365 is Now Available
At the conference, Congruence will present a poster titled "Identification of Allosteric GCase Correctors using Revenir™ for the treatment of GBA1-Parkinson's Disease." The abstract number for this presentation is 791 and it is scheduled for Sunday, September 29th from 1-3PM. Jeremy Dupaul-Chicoine, Associate Director of Biology at Congruence Therapeutics, will be the presenting author.
The company's efforts to develop effective treatments for GBA1-Parkinson's Disease have yielded positive results and they continue to optimize their chemical leads in hopes of discovering potential clinical candidates. This presentation at the International Congress of Parkinson's Disease and Movement Disorders serves as a testament to Congruence Therapeutics' dedication to improving the lives of those affected by this debilitating disease.
Filed Under: Business
0 Comments
Latest on The PennZone
- CryptaBox Introduces a Hardware Crypto Cold Storage Wallet
- YWWSDC Launches AI-Native Digital Asset Infrastructure, Merging Technical Innovation with US-Standard Compliance
- High-End Exterior House Painting in Boulder, Colorado
- Simpson and Reed Co-Founders Shardé Simpson, Esq. and Ciara Reed, Esq. Launch "Hello Wilma,"
- Report Outlines Key Questions for Individuals Exploring Anxiety Treatment Options in Toronto
- Rande Vick Introduces Radical Value, Challenging How Brands Measure Long-Term Value
- Lisa Mauretti Launches Peace of Mind Travel Coaching to Guide Fearful Travelers to Discover the World with Confidence
- New Year, New Home: Begin 2026 at Heritage at South Brunswick
- Food Journal Magazine Releases Its 'Best Food In Los Angeles Dining' Editorial Section
- Enders Capital: 25% Gains with Just -0.80% Maximum Monthly Drawdown in Volatile Debut Year 2025
- CES Spotlight Highlights Need for Strategic Review as Throughput Demands Evolve
- ASR Media, Social T Marketing & PR Announce Merger
- $780,000 Project for New Middle East Police Service with Deposit Received and Preliminary Design Work Underway for Lamperd: Stock Symbol: LLLI
- The 3rd Annual Newark Summit for Real Estate, Economic Development & Placemaking Returns February 9th
- Ski Safety Awareness Month highlights why seeing clearly and wearing modern protection matters more than ever
- Vent Pros Expands Operations into Arizona to Meet Growing Demand for Commercial Ventilation and Kitchen Hood Cleaning Services
- Klein Civil Rights Expands with New Offices in New York's Historic Woolworth Building
- Biz Hub Financial Hosts 9th Annual Client Appreciation Event, Awards $1,000 CARES Community Grant
- Green Office Partner Appoints Aaron Smith as Chief Revenue and Growth Officer
- A Family Completes a Full Circumnavigation of the Globe in a Self-Contained Camper Van